Abstract:Study question: In addition to chromosomal euploidy, can the transcriptome of blastocysts be used as a novel predictor of embryo implantation potential? Summary answer: This retrospective analysis showed that based on differentially expressed genes (DEGs) between euploid blastocysts which resulted and did not result in a clinical pregnancy, machine learning models could help improve implantation rates by blastocyst optimization. What is known already: Embryo implantation is a multifaceted process, with implantation loss and pregnancy failure related not only to blastocyst euploidy but also to the intricate dialog between blastocyst and endometrium. Although in vitro studies have revealed the characteristics of trophectoderm (TE) differentiation in implanted blastocysts and the function of TE placentation at the implantation site, the precise molecular mechanisms of embryo implantation and their clinical application remain to be fully elucidated. Study design, size, duration: This study involved 102 patients who underwent 111 cycles for preimplantation genetic testing for aneuploidies (PGT-A) between March 2022 and July 2023. Participants/materials, setting, methods: The study included 412 blastocysts biopsied at Day 5 [D5] or Day 6 [D6] for patients who underwent PGT-A. The biopsy lysates were split and subjected to DNA and RNA sequencing (DNA- and RNA-seq). One part was used for PGT-A to detect DNA copy number variations, whereas the other part was assessed simultaneously by RNA-seq to determine the transcriptome characteristics. To validate the reliability and accuracy of RNA-seq obtained from this strategy, we initially analyzed the transcriptome of blastocysts with chromosomal aneuploidies. Subsequently, we compared the transcriptomic features of blastocysts with different rates of formation (D5 vs D6) and investigated the network of interactions between key blastulation genes and the receptive endometrium. Then to evaluate the implantation potential of euploid blastocysts, we identified DEGs between euploid blastocysts that resulted in clinical pregnancy (defined as the presence of a gestational sac detected by ultrasound after 5 weeks) and those that did not. These DEGs were then employed to construct a predictive model for optimizing blastocyst selection. Main results and the role of chance: The successful detection rate of PGT-A was remarkably high at 99.8%. The RNA data may infer aneuploidy for both trisomy and monosomy. Between the euploid blastocysts that formed on D5 and D6, 187 DEGs were predominantly involved in cell differentiation for embryonic placenta development, the PPAR signaling pathway, and the Notch signaling pathway. These D5/D6 DEGs also exhibited a functional dialog with the receptive phase endometrium-specific genes through protein-protein interaction networks, indicating that the embryo undergoes further differentiation for post-implantation development. Furthermore, a modeling strategy using 280 DEGs between blastocysts leading to successful clinical pregnancies or failing to produce clinical pregnancies was implemented to refine the euploid embryo optimization, achieving areas under the curves of 0.88, 0.71, and 0.84 for the random forest (RF), support vector machine, and linear discriminant analysis models, respectively. Finally, a retrospective analysis of 83 transferred euploid blastocysts using the RF model identified three types of euploid embryos with a decreasing trend in implantation potential. Notably, the implantation rate of the good group was significantly higher than that of the moderate group (88.6% vs 50.0% P = 0.001) and that of the moderate group was higher than that of the poor group (50.0% vs 20.8%, P = 0.035). Limitations, reasons for caution: The sample size was insufficient; thus, a prospective study is needed to verify the clinical effectiveness of the above model. Because we did not analyze blastocysts that led only to biochemical pregnancies but failed clinical pregnancies separately, our classification system still must be modified to screen these embryos. Wider implications of the findings: Transcriptomic analysis of blastocysts offers a novel approach for predicting embryo implantation potential, which can be utilized to optimize clinical embryo selection. The ranking system may be effective in reducing the times and costs involved in achieving a clinical pregnancy. Study funding/competing interest(s): This study was funded by the "Pioneer" and "Leading Goose" R&D Program of Zhejiang (No. 2023C03034), the National Natural Science Foundation of China (82101709), and the National Key Research and Development Program for Young Scientists of China (No. 2022YFC2702300). The authors state no competing interests. Trial registration number: N/A.

Effects of Ovarian Stimulation on Embryo Euploidy: an Analysis of 12874 Oocytes and 3106 Blastocysts in Cycles with Preimplantation Genetic Testing for Monogenic Disorders

Effects of ovarian stimulation on embryo euploidy: an analysis of 12 874 oocytes and 3106 blastocysts in cycles with preimplantation genetic testing for monogenic disorders

Aneuploidy Rates and Clinical Pregnancy Outcomes after Preimplantation Genetic Testing for Aneuploidy Using the Progestin-Primed Ovarian Stimulation Protocol or the Gonadotropin-Releasing Hormone Antagonist Protocol

Oocytes With Smooth Endoplasmic Reticulum Aggregates May Not Impact Blastocyst Euploidy Rate

Correlation between controlled ovarian stimulation protocols and euploid blastocyst rate in pre-implantation genetic testing for aneuploidy cycles

#284 : Impact of Dosage and Duration of Exogenous Gonadotropins on Embryonic Genetic Status and Cumulative Live Birth Rate: A Secondary Analysis of a Multicenter, Randomized Controlled Trial

Excessive Exogenous Gonadotropins and Genetic and Pregnancy Outcomes after Euploidy Embryo Transfer A Secondary Analysis of a Randomized Clinical Trial

[Effect of Exogenous Gonadotropin Dosage on Embryo Aneuploidy Rate and Pregnancy Outcome in Patients of Preimplantation Genetic Test].

Euploidy rates among preimplantation genetic testing for aneuploidy cycles with oral dydrogesterone primed ovarian stimulation or GnRH antagonist protocol.

Effect of Blastocyst Morphology and Developmental Rate on Euploidy and Live Birth Rates in Preimplantation Genetic Testing for Aneuploidy Cycles With Single-Embryo Transfer

Blastocyst euploidy rates in low-prognosis patients according to the POSEIDON criteria: a retrospective analysis of 3016 embryos

Analysis of a preimplantation genetic test for aneuploidies in 893 screened blastocysts using KaryoLite BoBs: a single-centre experience

Multi-omics PGT: re-evaluation of euploid blastocysts for implantation potential based on RNA sequencing

Euploidy rates among first preimplantation genetic testing for aneuploidy cycles treated by oral dydrogesterone primed ovarian stimulation or the flexible gonadotropin-releasing hormone antagonist protocol

Comparative Analysis of Pregnancy Outcomes in Preimplantation Genetic Testing for Aneuploidy and Conventional in Vitro Fertilization and Embryo Transfer: a Stratified Examination on the Basis of the Quantity of Oocytes and Blastocysts from a Multicenter Randomized Controlled Trial.

Dosage of exogenous gonadotropins is not associated with blastocyst aneuploidy or live-birth rates in PGS cycles in Chinese women

Exploring the Efficacy and Beneficial Population of Preimplantation Genetic Testing for Aneuploidy Start from the Oocyte Retrieval Cycle: a Real-World Study

The impact of LH-containing gonadotropin stimulation on euploidy rates in preimplantation embryos: antagonist cycles

Total gonadotropin dose did not affect euploid blastocyst rates: an analysis of more than 19,000 oocytes

DOES POOR BLASTOCYST MORPHOLOGY IMLPY LOWER EUPLOIDY RATE IN PATIENTS UNDERGOING PGT-A?

Euploid Blastocyst Rates in Patients from POSEIDON Groups 3 and 4 Using Propensity Score Matching